Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference

Targets $36 Billion TAM in Early Cancer Detection and MRD. HENDERSON, Nev., Sept. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract1 at the European Society of Medical Oncology...